ArticlePsychiatry investigation2010
Bone density in chronic schizophrenia with long-term antipsychotic treatment: preliminary study.
Article in Psychiatry investigation, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 37 citations in OpenAlex.
- The neglected association between schizophrenia and bone fragility: a systematic review and meta-analyses.Translational psychiatry · 2024Pooled it
- Bone Mineral Density in Schizophrenia: An Update of Current Meta-Analysis and Literature Review Under Guideline of PRISMA.Medicine · 2015Pooled it
- Psychotropic medication use and bone loss in men: longitudinal study.BJPsych open · 2026Article
- Analysis of the Influencing Factors of Aripiprazole and Risperidone on Bone Mass Health in Patients with Chronic Schizophrenia: A Cross-Sectional Study.Neuropsychiatric disease and treatment · 2026Article
- The Association Between Antipsychotics and Bone Fragility: An Updated Comprehensive Review.Diagnostics (Basel, Switzerland) · 2024Review
- Significance of Duodenal Prolactin Receptor Modulation by Calcium and Vitamin D in Sulpiride-Induced Hyperprolactinemia.Medicina (Kaunas, Lithuania) · 2024Article
- Does clozapine really affect bone mineral density? An experimental study.Journal of orthopaedic surgery and research · 2021Article
- A trans-ethnic two-stage polygenetic scoring analysis detects genetic correlation between osteoporosis and schizophrenia.Clinical and translational medicine · 2020Article
- Serum Prolactin and Bone Mineral Density in Schizophrenia: A Systematic Review.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2019Article
- Expression of prolactin receptors in the duodenum, kidneys and skeletal system during physiological and sulpiride-induced hyperprolactinaemia.Endocrine · 2018Article
- Haloperidol affects bones while clozapine alters metabolic parameters - sex specific effects in rats perinatally treated with phencyclidine.BMC pharmacology & toxicology · 2017Article
- Effects of Antipsychotics on Bone Mineral Density in Patients with Schizophrenia: Gender Differences.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2016Review
- Factors associated with decreased bone mineral density in postmenopausal women with schizophrenia.Clinical interventions in aging · 2016Article
- Parameters of Calcium Metabolism Fluctuated during Initiation or Changing of Antipsychotic Drugs.Psychiatry investigation · 2016Article
- Bone Mineral Density as a Marker of Cumulative Estrogen Exposure in Psychotic Disorder: A 3 Year Follow-Up Study.PloS one · 2015Article
- The Effects of Prolactin-Raising and Prolactin-Sparing Antipsychotics on Prolactin Levels and Bone Mineral Density in Schizophrenic Patients.Noro psikiyatri arsivi · 2014Article
- Atypical antipsychotic drugs inhibit trabecular bone accrual in C57BL/6J mice.International journal of body composition research · 2013Article
- Osteoporosis and fracture risk in people with schizophrenia.Current opinion in psychiatry · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveDecreased bone mineral density has been found in the chronic schizophrenic patients who have been given a long-term administration of antipsychotics. Hyperprolactinemia from the antipsychotics and the negative symptom of schizophrenia were considered as the causes for this finding. In this study, the effect of hyperprolactinemia and the negative symptom of schizophrenia on bone mineral density was investigated on male schizophrenic patients.
methodsThe cross-sectional study was carried out with the subjects of 45 male schizophrenic patients who have undertaken the monotherapy with risperidone, olanzapine and clozapine for at least one year. The demographic factors, clinical symtoms, bone mineral density and hematological test were examined for all the subjects.
resultsNo significant relationship was found between hyperprolactinemia and the decreased bone mineral density in the subjects. The negative schizophrenia symptom of the subjects showed a significant effect on the decreased bone mineral density.
conclusionThe decreased bone mineral density finding in the male schizophrenic patients may be caused by the negative schizophrenia symptom rather than the hyperprolactinemia due to the antipsychotics. Additional studies are further required regarding other factors that may affect the decreased bone mineral density such as activity, calcium intake and exposure to sunlight.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.